Announcements Trials
Browse Landscape

Phase

Phase 3 7Phase 2 7Phase NA 2Phase 4 2Phase 1/2 2Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 1

Conditions

Thyroid Neoplasms 1Differentiated Thyroid Cancer 1

Interventions

pembrolizumab 65Cisplatin 42Cetuximab 36Radiotherapy 28Nivolumab 26Paclitaxel 22Carboplatin 22Docetaxel 20durvalumab 14Radiotherapy, Intensity-Modulated 12Fluorouracil 12Cyclophosphamide 11tremelimumab 9Gemcitabine 9Ipilimumab 8fludarabine 7avelumab 7Erlotinib Hydrochloride 7toripalimab 6epacadostat 6cemiplimab 6Radiosurgery 6Interleukin-2 6Capecitabine 6Bevacizumab 6spartalizumab 5Celecoxib 5zalutumumab 4tislelizumab 4fludarabine phosphate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Thyrotropin Alfa × Head & Neck × Clear all
NCT04137185 2024-03-06

Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1/2 Completed
64 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT03276988 2020-09-09

Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients

Genexine, Inc.

Phase 1/2 Completed
8 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡